Results 71 to 80 of about 11,587 (189)

5‐HT2A receptor agonism by tert‐leucinamide and valinamide synthetic cannabinoids: In vitro and in vivo evidence

British Journal of Pharmacology, Volume 183, Issue 16, Page 4715-4734, August 2026.
Abstract Background and Purpose New synthetic cannabinoid receptor agonists (SCRAs) are associated with severe adverse effects, including unexpected psychiatric symptoms. These compounds are mainly active through their potent agonism on the cannabinoid receptors CB1 and CB2.
Giorgia Corli, Deborah Rudin, Dino Luethi, Matthias E. Liechti, Sabrine Bilel, Matteo Marti, Henrik Green, Manuela Carla Monti, Caitlyn Norman   +8 more
wiley   +1 more source

Tourism, human–wildlife interactions, and wildlife trade in the globalizing Amazon

Conservation Science and Practice, Volume 8, Issue 8, August 2026.
Tourism in the globalizing Peruvian Amazon contributes to harmful human–wildlife interactions and the wildlife trade, with tourists participating in activities such as handling wildlife, taking selfies with animals, purchasing live animals, and wild meat consumption.
Christian J. Rivera, William R. Travis, Miguel Caireta Camps, Ruth M. Rocker, Javier Velásquez Varela, Pamela Montero Alvarez, Agustín Fuentes, David S. Wilcove   +7 more
wiley   +1 more source

Outpatient Young Adults with Concurrent Disorders: A Naturalistic Study of Clinical Characteristics and DBT Skills Training Outcomes

Early Intervention in Psychiatry, Volume 20, Issue 8, August 2026.
ABSTRACT Introduction This naturalistic study characterized clinical profiles of outpatient young adults with concurrent substance use and nonsubstance mental health symptoms in addition to evaluating reach and outcomes of a dialectical behaviour therapy skills training group.
Kiefer D. Cowie, Asher Weller, Melissa Griffin, Dafna Sara Rubin‐Kahana, Mahalia Dixon, Jake Ross, Bahar Amani, Susan Dickens, Lisa D. Hawke, Joanna Henderson, Darren Courtney   +10 more
wiley   +1 more source

From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence‐Based Policy and Practice

Pharmacology Research & Perspectives
The recent review of a new drug application for MDMA‐assisted therapy for posttraumatic stress disorder by the United States' Food and Drug Administration (FDA) highlighted epistemological and methodological challenges for evidence assessments.
Eduardo Ekman Schenberg
doaj   +1 more source

New Frontiers or a Bursting Bubble? Psychedelic Therapy Beyond the Dichotomy

Frontiers in Psychiatry, 2021
Tehseen Noorani, Jonny Martell
doaj   +1 more source

Las propiedades farmacocinéticas del ayahuasca / The pharmacological properties of ayahuasca [PDF]

Liberabit, 2015
RESUMEN Se describe las características químicas y los efectos del consumo del ayahuasca para conocer el estado actual de los descubrimientos existentes hasta la fecha sobre sus propiedades farmacocinéticas.
Guillermo Saúl Escobar Cornejo
doaj  

Corrigendum: The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming within a Large Database of Psychoactive Substance Reports

Frontiers in Neuroscience, 2018
Camila Sanz, Federico Zamberlan, Earth Erowid, Fire Erowid, Enzo Tagliazucchi, Enzo Tagliazucchi   +5 more
doaj   +1 more source

Diverse avenues of research support the transmethylation theory of psychosis: implications for neuroprotection

Exploration of Neuroprotective Therapy
Transmethylation in the context of psychiatry has historically referred to the enzymatic transfer of a methyl group from one biochemical to another, whose resulting function can change so dramatically that a biochemical like tryptamine, for example, is ...
Christine L. Miller
doaj   +1 more source

Hallucinogen-Psychosis Associations Are Confounded by Baseline Psychiatric History. [PDF]

J Clin Psychiatry
Steinle JT, Shankar S, Siegel JS, Cabassa LJ, Adams DR, Cavazos-Rehg P, Agrawal A, Nicol GE, Grucza R, Xu KY.   +9 more
europepmc   +1 more source

Changes over time in hallucinogen-related emergency department visits in Ontario, Canada. [PDF]

Addiction
Myran DT, MacDonald-Spracklin R, Levesque AR, Pugliese M, Fiedorowicz JG, McDonald AJ, Rosenblat JD, Colman I, Zein J, Solmi M.   +9 more
europepmc   +1 more source